Eli Lilly Blasted Over Cymbalta Labeling In Side Effect Row
Eli Lilly and Co. downplayed the withdrawal risk of its antidepressant drug Cymbalta to the point of fraud, a pair of women told a Virginia federal jury Monday, saying the company...To view the full article, register now.
Already a subscriber? Click here to view full article